• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BD recalls hundreds of thousands of Alaris pumps due to multiple issues

BD recalls hundreds of thousands of Alaris pumps due to multiple issues

March 6, 2020 By Sean Whooley

Becton DickinsonThe FDA today warned on a Class I recall of Becton Dickinson (NYSE:BDX) Alaris system infusion pumps due to multiple system errors, software errors, and use-related errors.

All lots of five different models of the Alaris system were included in the recall that Becton Dickinson initiated on Feb. 4. In total, the company recalled 774,000 devices in the U.S. According to a news release, there have been 55 reported injuries and one death due to the issues. These were the affected models:

    • BD Alaris System PC Unit Model 8000, software versions 9.5 and prior.
    • BD Alaris System PC Unit Model 8015, software versions 9.33 and prior, and software version 12.1.0.
    • BD Alaris Pump Module Model 8100, software versions 9.33 and prior, and software version 12.1.0.
    • Alaris Syringe Module Model 8110, software versions 9.33 and prior, and software version 12.1.0.
    • Alaris PCA Module Model 8120, software versions 9.33 and prior, and software version 12.1.0.

Affected Alaris PC units with the software version 9.33 and older were distributed between July 2004 and Oct. 31, 2019, while the affected PC units with the software version 12.1.0 were distributed between Dec. 18, 2019, and Jan. 23, 2020, according to an FDA release.

The modules with the software version 9.33 and older have experienced software/system errors, delay options programming, low battery alarm failures, “keep vein open” (KVO) and “end of infusion” alarm priority issues and user-related errors with custom concentration programming.

Modules with software version 12.1.0 were reported to experience low battery alarm failures, KVO and “end of infusion” alarm priority issues, custom concentration programming user errors and the KVO rate was reportedly unavailable when using delay options programming.

The errors could lead to a delay in infusion, the interruption of infusion, slower-than-expected delivery of medication and faster-than-expected delivery of medication. BD/CareFusion 303 intend to contact all affected customers to begin the scheduling process for the necessary software update when the software is made available. Without the update, affected devices may remain vulnerable to the risk of the system and software errors.

BD’s Alaris system is an infusion pump and vital signs monitoring system designed to deliver fluids, medications, blood and blood products in controlled amounts.

Filed Under: Blood Management, Drug Pumps, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: becton dickinson, FDA

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy